This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 11. (Cancelled)

12. (New) A synthesized peptide comprising one or more sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:11.

13. (New) An osteogenetic accelerator comprising the peptide set forth in claim 12, or a pharmacologically acceptable salt thereof, attached to a biocompatible carrier.

14. (New) An osteogenetic accelerator comprising the peptide of claim 12, or a pharmacologically acceptable salt thereof, mixed with, dissolved in, or suspended in aqueous solvent.

15. (New) A synthesized peptide comprising the sequence SEQ ID NO:11.

16. (New) An osteogenetic accelerator comprising the peptide set forth in claim 15, or a pharmacologically acceptable salt thereof, attached to a biocompatible carrier.

17. (New) The osteogenetic accelerator according to claim 16, wherein the carrier is selected from a group consisting of a ceramic, an artificial bone, a covalently cross-linked gel of alginate, and a gel of collagen, hyaluronic acid,

calcium sulfate, polylactic acid, polyglycolic acid, hydroxyapatite, tricalcium phosphate, starch, chitin/chitosan, agarose, or dextran.

18 (New) The osteogenetic accelerator according to claim 16 which contains 0.01 to 50 parts by weight of the peptide per 100 parts by weight of the carrier.

19. (New) An osteogenetic accelerator comprising the peptide of claim 15, or a pharmacologically acceptable salt thereof, mixed with, dissolved in, or suspended in aqueous solvent.

20. (New) The osteogenetic accelerator according to claim 19, wherein the aqueous solvent is physiological saline solution or a physiologically acceptable aqueous solution selected from a group consisting of mannitol, sucrose, lactose, maltose, glucose, and fructose.

21. (New) The osteogenetic accelerator according to claim 19 or 20, wherein the concentration of the peptide is 0.001% to 5% with respect to the aqueous solvent.

22. (New) The osteogenetic accelerator as set forth in claim 16 which is used for treating a bone fracture by inducing bone formation at the fracture site or for inhibiting a decrease in bone substance.

23. (New) The peptide of claim 15, wherein the peptide N-terminal is acetylated, or the peptide C-terminal is amidated, or both the N-terminal is acetylated and the C-terminal is amidated.

24. (New) An osteogenetic accelerator comprising a physiologically acceptable salt of the peptide set forth in claim 15.